1.Effect of the Pegylation of Trimeric ? Peptide on It's Anti-metastasis Activity
China Pharmacy 2005;0(13):-
OBJECTIVE: To observe the effect of the polyglycol (PEG) modification of trimeric ? peptide(?3) on it’s anti-metastasis ability. METHODS: Using adhesion test to study the effects of ?3 and ?3-PEG on the adhesion of tumor cells to FN. Using artificial basal membrane to study the effects of ?3 and ?3-PEG on the invasion and recombination of basal membrane of tumor cells. RESULTS: Comparing to negative control,?3 and ?3-PEG could both inhibit the adhesion of SMMC-7721 and HCCLM6 tumor cells to FN with time-dependently(P
2.Study of correlation factors for diabetes pathogenesis in Uygur Nationality in Urumuqi Region
Chinese Journal of Diabetes 2008;16(9):563-565
Objective To Study the correlation factors for diabetes pathogenesis of Uygur Nationality in Urumuqi.Methods A cluster sampling was done in 1002 Uygur people aged 25 to 74 years in a part of working units and living area in Urumuqi.All the people received 75g oral glucose tolerance test.Waist and hip circumference,blood pressure,height and body weight were measured.A questionnaire involved in the family history,diet,physical activity and the expenditure on diet was taken.Results(1)63% of the people was male,while 37% was female in our study.The constituent ratio of age was as following:25y~,23.08%;35y~,36.90%;45y~,19.64%;55y~,14.86%and 65y~,5.51%.(2)The prevalence of DM in the study was 14.69%,the abnormality of glucose metabolism was 29.89%.(3)The correlation factors of diabetes were family history of diabetes(OR 0.59),age(OR 0.83),high blood pressure(OR 0.912),waist-to-hip ratio(OR 3.851)and financial spending on diet(OR 5.279) in logistic regression analysis.Conclusions Diabetes-correlated factors are high financial spending on food especially meat products and little cellulose intake,high waist-to-hip ratio.To decrease the prevalence rate of diabetes in Uygur nationality,it is most important to change the diet habit and decrease intra-abdominal fat deposition
3.Protective effect of the total flavonoids of drynariae on renal reperfusion injury after hemorrhagic shock
International Journal of Traditional Chinese Medicine 2017;39(4):339-342
Objective To investigate the protective effect of total flavonoids of drynaria on hemorrhagic shock reperfusion renal injury.Methods The 30 Sprague-Dawley rats were randomly divided into 3 groups: sham operation group, experimental group (hemorrhagic shock group) and drynaria fortunei group, 10 in each group. In drynaria fortunei group and experiment group, the blood from the femoral artery was with drawn until the mean arterial pressure reached 40 mmHg in 90 min, and then the withdrawn blood transfusion were reinfused and blood pressure recovered to the base value of 90%. The rats of drynaria fortunei group were given intraperitoneal injection of Drynaria total flavonoid 300 mg/kg, and experimental group and sham operation group were injected with 3 ml physiological saline. Blood creatinine (SCr) levels, the renal cell apoptosis index, the expression of Bcl-2 and mRNA Bax in kidney were detected. Results Compared with the experimental group, serum SCr (78.36 ± 5.31 mmol/Lvs. 151.43 ± 11.8 mmol/L) of drynaria fortunei group decreased significantly (P<0.01); the renal cell apoptosis (19.56% ± 4.37%vs. 14.31% ± 2.83%), the expression level of Osteopractic rats of Bax group mRNA (1.24 ± 0.05vs. 0.91 ± 0.07) of drynaria fortunei group decreased significantly; and the Bcl-2 mRNA (0.65 ± 0.05vs. 1.38 ± 0.07) and the expression level and Bcl-2/bax ratio (0.52 ± 0.06vs. 1.51 ± 0.08) of drynaria fortunei group increased significantly (P<0.01).Conclusions The drynaria total flavonoids on rats with hemorrhagic shock and resuscitation of renal injury has a protective effect, and its mechanism may improve the expression of Bcl-2 and mRNA, increase the ratio of bcl-2/bax, and inhibit or block the apoptosis of renal tissue.
4.Translational research progress in malignant lymphoma
Journal of Leukemia & Lymphoma 2017;26(2):74-75
Rituximab in the combination of CHOP regimen has been widely used as the standard treatment of several kinds of B cell non-Hodgkin lymphoma (B-NHL),but there are still about 1/3 of the late B-NHL patients become primary and secondary resistant to the drug.Recently,many translational research progress in malignant lymphoma promoted the development of promising candidate drugs for the treatment of lymphoma.The advances in translational research field were summarized in this manuscript.
5.Updates in chimeric antigen receptor T-cell therapy for lymphoma
Journal of Leukemia & Lymphoma 2017;26(1):3-4
Tremendous success has emerged in chimeric antigen receptor (CAR)-T cell therapy over the past few years, especially in leukemia and lymphoma. The first CAR-T cell product might be available in America in 2017 due to the emergence of the critical results. This paper focused on the key data presented at the 58th American Society of Hematology Annual Meeting.
6.Survey of Irrational Use of Anti-tumor Immune Enhancement Drugs
China Pharmacist 2017;20(1):130-132
Objective:To investigate and analyze the rational use of anti-tumor immune enhancement drugs in our hospital. Meth-ods:The annual use data of anti-tumor immune enhancement drugs in our hospital in 2015 were collected, and then statistically ana-lyzed and evaluated combing with the medical history information. Results: There were 12 varieties and 19 specifications of adjuvant anti-tumor immune enhancement drugs in our hospital, which accounted for 15. 87% of the total sum. Totally 25 481 patients used ad-juvant anti-tumor immune enhancement drugs, which occupied 29. 84% of the total medicine afford. The adjuvant anti-tumor immune enhancement drugs showed lots of irrational use in clinics, and the main irrationity was overuse and off-label use. Conclusion: It is necessary to strengthen prescription evaluation for anti-tumor immune enhancement drugs, which needs controlled and rational use.
7.Advances in the diagnosis and treatment of mantle cell lymphoma
Chinese Journal of Clinical Oncology 2016;43(19):835-839
Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin's lymphomas (NHLs). MCL comprises distinct subtypes with different pathological characteristics and clinical features. However, MCL remains incurable by intensified first-line regimens con-taining cytarabine and involving consolidation with high-dose therapy and autologous stem cell transplantation. Recently discovered somatic mutations and aberrant intracellular signaling pathways have been demonstrated to play an essential role in the pathogenesis of MCL. The related novel therapeutics, such as Btk inhibitors, PI3K inhibitors, and immune modulators, have exhibited promising ther-apeutic effects on untreated or even relapsed/refractory MCL. The development of an efficient combination therapy is urgently need-ed to improve the survival of MCL patients in the future.
8.The Retrieval and Appraisal of Medical Ethics Information Resources on Internet
Chinese Medical Ethics 1995;0(02):-
By the way of searching engines and finding website linkages, the author retrieved the domestic and foreign medical ethics information resources on internet,enumerated some main websites related to medical ethics, analyzed the present condition,and suggested that we should hasten the construction of medical ethics information resources on internet.
10.Progress of clinical transformation research in malignant lymphoma in 2013
Journal of Leukemia & Lymphoma 2014;23(3):141-143
Advances in clinical transformation research has facilitated discovery of a number of novel somatic mutations and aberrant intracellular signaling pathways involved in malignant proliferative B-cell lymphoma.Meanwhile,small molecular inhibitors targeting those mutation genes or signaling pathways have also been shown to be effective in treating relapsed and refractory B-cell non-Hodgkin lymphoma.This paper reviewed important discoveries in clinical transformation research in lymphoma field in 2013.